Biogen Can't Escape Amended Antitrust Suit Over MS Drug

By Dorothy Atkins · January 28, 2026, 10:39 PM EST

Biogen Inc. must face health plans' claims that it bribed pharmacy benefit managers to stifle generics competition for its multiple sclerosis drug Tecfidera, after an Illinois federal judge found Wednesday that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

IN RE: TECFIDERA ANTITRUST LITIGATION

Case Number

Court

Illinois Northern

Nature of Suit

Anti-Trust

Date Filed

August 16, 2024

Recent Articles By Dorothy

January 21, 2026
AI Recruiting Co. Eightfold Sued Over Job Applicant 'Dossiers'
January 12, 2026
Gov't Fights Block Of EOs Curbing Federal Unions At 9th Circ.
December 18, 2025
UAW Leaders Deleted Retaliation Plot Texts, Monitor Finds
December 01, 2025
Ex-Immigration Judge Accuses DOJ Of Political Retaliation
November 14, 2025
9th Circ. Judge Rips Feds For 'Trying To Suppress Speech'
November 12, 2025
NCAA, Volunteer Coaches Cut $303M Wage-Fixing Deal
November 06, 2025
Cal Poly Athletes Rip NIL Deal For Impact On Women's Sports
November 04, 2025
Calif. Justices Doubt 'Illegible' Arb. Pact Is Enforceable
October 20, 2025
9th Circ. Judges Doubt DOD's 'Broad' Transgender Troop Ban
October 02, 2025
9th Circ. Says DOL Benefits Board Must Redo Atty Fees